(Reuters) - Johnson & Johnson is set to pay more than $1 billion to resolve a U.S. civil investigation into the marketing of its Risperdal antipsychotic drug, Bloomberg News reported on Thursday, citing anonymous sources.
The company reached a deal last week with the U.S. attorney in Philadelphia. The deal does not resolve negotiations over a possible criminal plea, the report said.
Johnson & Johnson spokeswoman Teresa Mueller said the company does not comment on rumors or speculation.
In August, J&J said it reached an agreement related to a misdemeanor charge stemming from the Risperdal investigation, although some issues remained unresolved.